9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Cybin Inc. (HELP)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 3,832,843 | $18,397,646 | -1% | 0.36% |
| 2. | Millennium Management Israel Englander | 2,415,841 | $11,596,037 | +135% | 0% |
| 3. | Deep Track Capital David Kroin | 1,313,137 | $6,303,058 | -30% | 0.1% |
| 4. | Sphera Global Healthcare Fund Doron Breen And Mori Arkin | 987,090 | $4,738,032 | +20% | 0.75% |
| 5. | Citadel Investment Group Ken Griffin | 877,347 | $4,211,265 | +9% | 0% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,290 | $68,017 | 0.01% | |
| 2. | 6 | $40 | 0% | |
| 3. | 100 | $0 | 0% |
News See All
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers
TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential.
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Hedge Fund Resource Center